2024 Update of Chinese Guidelines for Management of Hyperuricemia and Gout Part II: Recommendations for Patients With Common Comorbidities
International Journal of Rheumatic Diseases · 2025-08 · 28 (8)
DOI: 10.1111/1756-185x.70402 ↗Kurz gefasst
Leitlinie in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 24.08.2025. Verfasst von Changgui Li und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China. Hauptthemen laut MEDLINE: Hyperuricemia, Gout, Gout Suppressants. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Projects of International Cooperation and Exchange NSFC.
Abstract (Originalsprache)
Objective
The aim of this updated guideline is to provide comprehensive recommendations for the management of gout in patients with common comorbidities, such as chronic kidney disease (CKD), cardiovascular disease (CVD), diabetes, osteoarthritis (OA), and gastrointestinal disorders.
Methods
This guideline was developed by a multidisciplinary expert panel consisting of specialists in endocrinology, rheumatology, nephrology, cardiology, gastroenterology, and methodology. The development process adhered to standard methodologies, including PICO (population, intervention, comparator, and outcomes) question deconstruction, systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) for evidence and recommendation evaluation, Delphi voting, and expert consensus.
Results
The guideline presents 26 evidence‐based recommendations addressing seven clinical questions for patients with hyperuricemia and gout in the context of comorbidities. Key recommendations include the maintenance of strict serum urate targets, particularly for patients with CKD stage ≥ 3, chronic gouty arthritis, and OA, in order to prevent disease progression. In patients with CVD or diabetes, intra‐articular triamcinolone is preferred over systemic glucocorticoids. Prioritized anti‐inflammatory treatments for patients with CKD, gastrointestinal diseases, and OA are recommended. The guideline also introduces emerging therapies, such as interleukin‐1 inhibitors and selective urate transport inhibitors, as potential treatment options for refractory cases.
Conclusion
The update offers a comprehensive, patient‐centered approach to managing gout, particularly in individuals with associated comorbidities. Multidisciplinary collaboration and emerging new treatments and evidence ensure the optimization of the recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
- Department of Rheumatology, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
- Department of Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
ORCID-Profile: Chengfu Xu, Bo Ban, Jia Liu, Fei Yan, Yaolong Chen, Jiajun Zhao
Förderung
- National Key Research and Development Program of China
- Projects of International Cooperation and Exchange NSFC
Zitieren
APA
Li, C., Sun, M., Liu, Z., Li, D., Wang, C., Tian, Z., Dai, Y., Feng, Z., Xu, C., Zhao, D., Wei, F., Ban, B., Xie, C., An, Z., Liu, J., Li, Z., He, Y., Li, X., Yan, F., …, & Zhao, J. (2025). 2024 Update of Chinese Guidelines for Management of Hyperuricemia and Gout Part II: Recommendations for Patients With Common Comorbidities. International Journal of Rheumatic Diseases, 28(8). https://doi.org/10.1111/1756-185x.70402
Vancouver
Li C, Sun M, Liu Z, Li D, Wang C, Tian Z, et al. 2024 Update of Chinese Guidelines for Management of Hyperuricemia and Gout Part II: Recommendations for Patients With Common Comorbidities. International Journal of Rheumatic Diseases. 2025;28(8). doi:10.1111/1756-185x.70402
BibTeX
@article{Li2025,
author = {Li, Changgui and Sun, Mingshu and Liu, Zhen and Li, Detian and Wang, Changqian and Tian, Zibin and Dai, Yuxiang and Feng, Zhe and Xu, Chengfu and Zhao, Dongbao and Wei, Feng and Ban, Bo and Xie, Chao and An, Zhenmei and Liu, Jia and Li, Zhuo and He, Yuwei and Li, Xinde and Yan, Fei and Han, Lin and Ma, Lidan and Cheng, Xiaoyu and Liu, Tian and Luo, Xufei and Cui, Lingling and Gong, Ying and Wang, Can and Chen, Yaolong and Lyu, Zhaohui and Yip, Ronald M L and Zhao, Jiajun},
title = {2024 Update of Chinese Guidelines for Management of Hyperuricemia and Gout Part II: Recommendations for Patients With Common Comorbidities},
journal = {International Journal of Rheumatic Diseases},
year = {2025},
volume = {28},
number = {8},
doi = {10.1111/1756-185x.70402}
}
EUVIMED